West Pharma Reports Strong Q1, Raises Full-Year Guidance, and Executes Significant Share Repurchase
WST sits 63% above its 52-week low of $199.89.
Summary
West Pharmaceutical Services reported strong first-quarter results, raised its full-year 2026 financial guidance, and repurchased $297.6 million in shares, signaling robust performance and management confidence.
Key Events · Earnings and Guidance · WST
-
Strong First Quarter 2026 Results
The company reported net sales of $844.9 million, a 21.0% increase (15.3% organic), and diluted EPS of $1.92, up 56.1% year-over-year. Adjusted-diluted EPS rose 46.9% to $2.13.
-
Full-Year 2026 Guidance Raised
West Pharmaceutical Services increased its full-year 2026 net sales guidance to a range of $3.295 billion to $3.350 billion (up from $3.215 billion to $3.275 billion) and adjusted-diluted EPS guidance to $8.40 to $8.75 (up from $7.85 to $8.20).
-
Significant Share Repurchase
The company repurchased 1.2 million shares for $297.6 million during Q1 2026, at an average price of $243.57 per share, under its previously announced program.
-
GLP-1 Market Driving Growth
GLP-1 related revenues contributed significantly, with elastomer revenues accounting for 10% and West Vantage revenues for 8% of total company sales in Q1 2026.
Analysis · WST · Industrial Applications And Services
West Pharmaceutical Services delivered a robust first quarter, significantly exceeding expectations with strong revenue and EPS growth. The company's decision to raise its full-year 2026 guidance for both net sales and adjusted EPS signals strong confidence in continued momentum, driven by high-value products and the GLP-1 market. Furthermore, the execution of a substantial share repurchase program, amounting to nearly $300 million, demonstrates a commitment to returning capital to shareholders and reflects management's positive outlook, especially as the stock trades near its 52-week high. This filing formalizes the positive news that was concurrently reported by news outlets.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1075 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WST was trading at $325.01 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $19.8B. The 52-week trading range was $199.89 to $322.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.